Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating ...

Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors,

Related Keywords

United States ,San Diego ,California ,Planegg Martinsried ,Pamela Keck ,Doloresj Schendel ,Society For Immunotherapy Of Cancer ,Prime Standard ,Chief Executive Officer ,End To Platform ,Switch Proteins ,Precision Pairing ,Cellular Oncology ,Driving Force ,Programmed Death Ligand ,Business ,